pioglitazone

Ligand id: 2694

Name: pioglitazone

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 93.59
Molecular weight 356.12
XLogP 3.66
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of type 2 diabetes.
In 2014, the EMA granted pioglitazone orphan designation for the treatment of adrenoleukodystrophy (ALD).
Mechanism Of Action and Pharmacodynamic Effects
Agonist of peroxisome proliferator-activated receptor gamma receptor (PPARγ) in target tissues for insulin action. Activation of these receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport and utilisation. This results in enhanced tissue sensitivity to insulin and reduced hepatic gluconeogenesis.
In ALD activation of PPARγ receptors by pioglitazone is postulated to reduce axonal degeneration by improving mitochondrial function in nerve cells [3].
External links